Lantheus Holdings (LNTH) Net Equity Issued and Repurchased (2014 - 2025)
Lantheus Holdings' (LNTH) quarterly Net Equity Issued and Repurchased came in at $2.0 million in Q1 2025, up 8.78% year-on-year from $1.8 million in Q1 2024, and up 21.88% on a QoQ basis from $1.6 million in Q3 2024.
Lantheus Holdings (LNTH) Net Equity Issued and Repurchased (2014 - 2025) Analysis & Trends
Lantheus Holdings (LNTH) has 11 years of Net Equity Issued and Repurchased data on file, last reported at $2.0 million in Q1 2025.
- On a quarterly basis, Net Equity Issued and Repurchased rose 8.78% year-over-year to $2.0 million in Q1 2025; TTM through Mar 2026 was $3.6 million, a 0.0% change from a year earlier, with the FY2024 full-year figure at $3.4 million, up 78.48% from the prior year.
- Net Equity Issued and Repurchased for Q1 2025 stood at $2.0 million, up from $1.6 million in the prior quarter.
- Over the last five years, Net Equity Issued and Repurchased for LNTH reached as high as $2.0 million in Q1 2025 and fell as low as -$1000.0 in Q4 2021.
- Historically, Net Equity Issued and Repurchased has averaged $950800.0 across 5 years, with a median of $869000.0 in 2022.
- Across the five-year window, Net Equity Issued and Repurchased dropped 7.92% in 2021 and jumped 93.94% in 2024, its largest moves.
- Year by year, Net Equity Issued and Repurchased stood at -$1000.0 in 2021, then soared by 79900.0% to $798000.0 in 2022, then rose by 24.44% to $993000.0 in 2023, then jumped by 63.85% to $1.6 million in 2024, then rose by 21.88% to $2.0 million in 2025.
- Per Business Quant data, the three most recent Net Equity Issued and Repurchased figures were $2.0 million in Q1 2025, $1.6 million in Q3 2024, and $1.8 million in Q1 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 500,000.00 |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 23.60 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Lantheus Holdings | 6.72 Bn | 6.22 Bn | 230.92 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 1.98 Mn |
| Mar 31, 2025 | 1.98 Mn |
| Sep 30, 2024 | 1.63 Mn |
| Sep 30, 2024 | 1.63 Mn |
| Mar 31, 2024 | 1.82 Mn |
| Mar 31, 2024 | 1.82 Mn |
| Sep 30, 2023 | 993,000.00 |
| Sep 30, 2023 | 993,000.00 |
| Mar 31, 2023 | 940,000.00 |
| Mar 31, 2023 | 940,000.00 |
| Sep 30, 2022 | 798,000.00 |
| Sep 30, 2022 | 798,000.00 |
| Mar 31, 2022 | 577,000.00 |
| Mar 31, 2022 | 577,000.00 |
| Dec 31, 2021 | -1,000.00 |
| Dec 31, 2021 | -1,000.00 |
| Sep 30, 2021 | 431,000.00 |
| Sep 30, 2021 | 431,000.00 |
| Mar 31, 2021 | 337,000.00 |
| Mar 31, 2021 | 337,000.00 |